Study guide
14.3 Delegation, Qualifications and Task Authority
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
14.3 Delegation, Qualifications and Task Authority
Key Takeaways Explain This Topic AI
Investigator oversight remains when qualified staff perform delegated activities.
Delegation documentation should be proportionate to the work.
A late log entry requires investigation of actual authorisation, training and performance dates.
Last updated: October 2026
Delegation, Qualifications and Task Authority
For example, a coordinator may transcribe a documented assessment using their own authorised account. That differs from independently making a medical causality decision outside their competence or signing as an investigator. Review who made the assessment, when they reviewed the information, and whether the reported data reflect that decision. A late signature may expose an oversight gap; it does not prove that no clinical review occurred, so investigate the evidence.
The Delegation of Authority (DOA) Log & The Non-Delegable Principle
Because a Principal Investigator cannot personally perform every clinical measurement, pharmacokinetic blood draw, and data entry across dozens of trial participants, tasks are delegated to qualified investigative site personnel. A common documentation tool for this process is the Site Delegation of Authority (DOA) Log (frequently titled the Site Signature and Delegation of Responsibilities Log ).
The Cardinal Principle of Site Oversight
Important
The Non-Delegable Principle: The Principal Investigator may delegate the performance of specific study-related tasks to qualified, trained individuals. However, the Principal Investigator CANNOT delegate ultimate legal, regulatory, and ethical responsibility for trial conduct, subject safety, and data integrity. The PI remains fully accountable for all actions performed by delegates.
Documenting delegation proportionately
Maintain evidence identifying the person, delegated activity and relevant period, with qualifications and training appropriate to the work. The investigator retains oversight. A delegation log is a common tool, but E6(R3) uses proportionate documentation and does not require every routine clinical-care activity to appear on one rigid sponsor form.
Authorise and train staff before they perform trial-specific activities. If an entry was added late, determine whether authorisation, qualifications and training actually existed at the time. Record the facts and current correction date; never backdate. The risk differs between missing paperwork for an already qualified routine activity and an untrained person making a restricted trial decision. Avoid treating a missing log signature as automatic proof of fabrication or trial-wide invalidity.
When responsibilities end or change, update delegations and system access. Verify coverage during leave and turnover so safety reports, review of urgent results and participant communication remain assigned. Training evidence should demonstrate the right person's understanding of the relevant protocol version and task; attendance alone may be inadequate for a specialised rater or product procedure.
Verifying Site Qualifications and Regulatory Documentation
A central responsibility of the CRA during pre-study qualification visits, site initiation visits, and routine monitoring is auditing site qualifications. The monitor must verify:
Qualifications, training and technical capability
Review current CVs or equivalent evidence, relevant professional permissions and restrictions, and task-specific competence. A universal two-year CV expiration or three-year GCP certificate renewal is not an ICH requirement. The investigator and institution should apply relevant regulatory and sponsor/institutional requirements and retain appropriate evidence.
Protocol and system training should address the person's responsibilities before affected activities. Changes require information/training appropriate to their impact. A new rater scale can require specialised preparation; a corrected phone number ordinarily does not require the same curriculum. Confirm understanding and practical competence rather than collecting attendance signatures alone.
Laboratories and technical services should have appropriate quality evidence, methods and reference ranges for their role. The particular accreditation or licence depends on the jurisdiction and service. Verify that staff have the information needed to interpret results at the relevant time. If ranges change, establish the effective period and assess affected decisions rather than assuming all historical results must be recalculated.
Matching tasks to competence and authority
Activity Key verification question
Medical care and eligibility decisions Is the person appropriately qualified, permitted under applicable requirements and delegated where appropriate?
Consent discussion Is the designee qualified and trained under the approved consent process?
Product management Is the person permitted to handle/dispense it and trained on the product instructions?
Specimen collection or processing Are qualifications, task training and necessary facilities documented?
Data entry and query response Is access attributable and consistent with delegation and the documented workflow?
Investigator endorsement Did an authorised investigator personally review and endorse the data under their own identity?
Delegation must reflect real work, not a form signed to excuse unauthorised activity later. A sponsor monitor can explain a discrepancy and request clarification but should not take over site medical decisions or impersonate site staff.
Onboarding a replacement team member
When a coordinator joins mid-study, identify the activities they will perform and the active protocol, system and manual versions. Verify relevant qualifications and training before those tasks begin, and establish access under the person’s own identity. Review coverage for urgent results and reports while the replacement is learning the workflow. A predecessor’s certificates and shared account cannot establish the new person’s competence or attribution. Document actual training and authorisation dates and verify the first relevant activities under the oversight plan; do not backdate the log to the previous employee’s departure.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ACRP CCRA Exam Content Outline .